In this study the effects of Garcinol 20% with Curcumin will be studied in patients with Non alcoholic Steatohepatitis (NASH)without liver cirrhosis(scarring of the liver tissue).
- Conditions
- Health Condition 1: K758- Other specified inflammatory liverdiseases
- Registration Number
- CTRI/2019/11/022147
- Lead Sponsor
- Sami Labs Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1.Patient has given informed consent for participation in this study.
2.BMI between 25 to 35 kg/m2.
3.Patient with presence of mild to moderate steatosis NASH (<= stage 2) without or with fibrosis(<= grade 2) by: Diagnosis of NASH based on elevated ALT and Ultrasonography.
4.Patient with controlled Diabetes, Hyper- lipidemia & Hypertension by stable dose for at least 3 months prior to screening.
1.Patients having age below 30 and above 65
2.Pregnant and lactating females not included in this study.
3.HbA1c more than 7.2.
4.Patients having other systemic complications like hepatic, renal and cardiac problems
5.Patient with history of alcoholism
6.Those are not willing to participate in trial and not ready to give written consent.
7.History of renal, pulmonary, epileptic, hematologic, cardio -vascular, neurological or psychiatric illness and immuno -eficiency diseases
8.Patients who are currently participating in any other clinical trials (since last 3 months).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method